Biotechnology
IHH Healthcare Expands 'IHH Catalyst' to North Asia to Accelerate Clinical Adoption of Healthcare Innovation
Building on the success of its inaugural programme in India, IHH Healthcare is launching IHH Catalyst | North Asia Edition to help startups in Hong Kong, Chinese Mainland and neighbouring markets turn healthcare innovation into real-world clinical impact. HONG KONG and SINGAPORE and KUALA L...
2026-07-27 11:00
1487
Seaweed extract shown to relieve prostate symptoms
In a breakthrough clinical trial undertaken by Australian biotechnology company Marinova, a unique seaweed extract has been shown to relieve the symptoms of benign prostatic hyperplasia (BPH). HOBART, Australia, July 27, 2026 /PRNewswire/ -- A randomised, double-blind, placebo-controlled clinical...
2026-07-27 07:00
1225
Nova Biomedical Advances Integrated Cell Line Development Workflows: NanoCellect products are now part of Nova Biomedical
WALTHAM, Mass., July 24, 2026 /PRNewswire/ -- Nova Biomedical today announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell sorting technology. This expands Nova Biomedical's capabilities in cell line development and strengthens its ability to support bio...
2026-07-24 22:05
3137
Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
PALMA DE MALLORCA, Spain, July 24, 2026 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, today announced that the last patient has completed their last visit (LPLV) in the company's Phase 2b/3 clinical trial of i...
2026-07-24 09:30
1991
ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406
SHANGHAI, July 24, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK0406, a novel long-acting antiviral-Fc conjugate (AFC) drug for influenza prophylaxis. The clini...
2026-07-24 09:00
1918
Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 23, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a ...
2026-07-24 08:02
6039
Fapon Showcases AI-Engineered Enzymes and Alzheimer's Solutions at ADLM 2026, Reinforcing North American Commitment
ANAHEIM, Calif., July 23, 2026 /PRNewswire/ -- Fapon, a trusted global IVD provider with deepening roots in North America, will exhibit at ADLM 2026 from July 26 to 30 in Anaheim, California. The company will introduce novel AI-engineered enzymes for molecular diagnostics alongside a full suite o...
2026-07-24 01:10
2373
AH-008 Achieves Key Clinical Milestone with Successful First Subject First Dose (FSFD) in Phase I Study for Prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
TAIPEI, July 23, 2026 /PRNewswire/ -- AnHorn Medicines today announced the successful completion of the first subject first dose in the Phase I clinical trial of AH-008, a first-in-class neuroprotective candidate being developed to prevent chemotherapy-induced peripheral neuropathy (CIPN). This m...
2026-07-23 22:00
2266
NYSE Content Update: Fourth Annual AI x Bio Summit to Commence at the NYSE
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, July 23, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begin...
2026-07-23 20:55
3372
PUBLIC TRUST IN HEALTH INNOVATION IS SHAPED MORE BY MINDSET THAN DEMOGRAPHICS, DNV RESEARCH FINDS
OSLO, Norway, July 23, 2026 /PRNewswire/ -- Public trust in health innovation
may be less predictable than healthcare organizations assume, according to new
research from DNV, the independent assurance and certification provider.
2026-07-23 20:34
1515
Moa Technology raises Series C round co-led by Oxford Science Enterprises and Supernova Invest
OXFORD, England, July 23, 2026 /PRNewswire/ -- Moa Technology ("Moa"), an agricultural biotechnology company focused on discovering novel mode of action herbicides, announces a £22.2 million Series C financing round, co-led by Oxford Science Enterprises ("OSE") and Supernova Invest ("Supernova")....
2026-07-23 17:00
2425
Haisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNH
BEIJING, July 23, 2026 /PRNewswire/ -- Haisco Pharmaceutical Group claimed today their independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (development code: HSK39297), has receivedmarketing approval from the National Medical Products Administration of China (NMPA) for t...
2026-07-23 14:08
1349
GHIT Fund Invests Approx. JPY 140 Million in a Portable Rapid Diagnostic System for Ebola Disease in a Joint Project Between Osaka Metropolitan University, K.K. DNAFORM, and INRB
TOKYO, July 23, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today an investment of JPY 140 million (approximately USD 862,000) in a project to develop a portable rapid diagnostic system for Ebola disease. The system is being jointly developed by Osaka Metrop...
2026-07-23 12:01
1859
Nona Biosciences Enters Research Collaboration with the Medical University of Vienna to Advance Fully Human Antibody Development for Infectious Diseases
Partnership grants Ignaz Semmelweis Institute access to Nona's H2L2 Harbour Mice ® transgenic mouse technology platform for translational antibody research CAMBRIDGE, Mass., July 22, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and de...
2026-07-23 08:55
2412
Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting
- Fixed-dose combination of ASC36 and ASC35 (ASC36_35 FDC) demonstrated superior weight loss compared to eloralintide in combination with tirzepatide in a diet-induced obese (DIO) animal model. HONG KONG, July 23, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that ...
2026-07-23 08:10
2542
Samsung Biologics Reports Second Quarter 2026 Financial Results
* Recorded Q2'26 revenue of KRW 1,321 billion and operating profit of KRW 586 billion * Delivered stable business performance through continued disciplined execution * Expanded global presence while advancing innovation and future growth initiatives INCHEON, South Korea, July 23, 2026 /PRNe...
2026-07-23 07:03
3234
HKEY-AI4AI-Atlas™ 1.0: HKeyBio Uses AI to Curate Autoimmune Model Datasets
HKEY-AI4AI-Atlas™ 1.0 uses AI-assisted dataset curation to support model selection, endpoint design and cross-species interpretation BOSTON and SUZHOU, China, July 22, 2026 /PRNewswire/ -- HKeyBio is building HKEY-AI4AI-Atlas™ 1.0, its AI-Assisted Autoimmune Model Data Atlas. The internal capabi...
2026-07-22 21:16
2445
Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management
* AI-Driven New Mechanism Discovery: Targeting an undisclosed novel mechanism empowered by PandaOmics, the PCC ISM9528 offers a potential first-in-class,brain -penetrant, non-opioid solution for pain management. * Superior Therapeutic Profile: In preclinical studies, ISM9528 demonstrated super...
2026-07-22 21:00
3909
Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease
SHANGHAI and MOLNDAL, Sweden, July 22, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") today announce at China Pharmaceutical Innovation Conference (CPIC) in Shanghai, the positive results fro...
2026-07-22 20:28
3797
Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors
Funding will support completion of IND-enabling activities and planned year-end
IND submission for TAVST01, Tikva's lead off-the-shelf CAR-T candidate
targeting B7-H3-positive solid tumors
SINGAPORE, July 22, 2026 /PRNewswire/ -- Tikva Allocell Pte. Ltd.
2026-07-22 19:03
3228
Week's Top Stories
Most Reposted
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
[Picked up by 324 media titles]
2026-08-05 11:34
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
[Picked up by 295 media titles]
2026-08-04 07:00
Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
[Picked up by 294 media titles]
2026-08-06 15:10
Vitafoods Asia Announces Strategic Move to Kuala Lumpur for 2027 Edition
[Picked up by 291 media titles]
2026-08-04 14:30
Gene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' Academy
[Picked up by 289 media titles]
2026-08-04 06:00
Most Read
Association of Trade and Commerce Reinforces Commitment to Supporting Singapore Enterprises Through Global Growth at The Entrepreneur Singapore 2026
2026-07-31 21:45
21021
CLASSYS Appoints Former Samsung Electronics Executive Vice President Jun-oh Yoon as CEO to Lead Its Next Stage of Global Growth
2026-07-31 23:12
10632
Oxford International Digital Institute Launches Oxford ELLT Express to Support Time-Sensitive Student Applications
2026-07-31 22:57
9634
